✦ LIBER ✦

Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen

✍ Scribed by Stenzinger, W. ;Blömker, A. ;Hiddemann, W. ;Loo, J.

Publisher: Springer-Verlag
Year: 1990
Weight: 556 KB
Volume: 61
Category: Article
ISSN: 1432-0584
DOI: 10.1007/bf02076700

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outpatient treatment of multiple myeloma

Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasone

✍ G. Egerer; U. Hegenbart; H. Salwender; R. Haas; U. Hahn; J. Schmier; A. Ho; H. G 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 120 KB

Cyclophosphamide, etoposide, vincristine

Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An international oncology study group (IOSG) phase II protocol

✍ Giles, Francis J.; Wickham, Nicholas R.; Rapoport, Bernardo L.; Somlo, George; L 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB

A 4-day continuous intravenous (CIV) infusion of vincristine and doxorubicin with highdose dexamethasone (VAD) regimen is a standard refractory multiple myeloma (MM) regimen. A Phase II study of a CEVAD regimen, i.e., VAD plus etoposide administered as a 96-hr continuous infusion, was carried out wi

Bortezomib in combination with thalidomi

Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma

✍ Dominik Dytfeld; Magdalena Matuszak; Krzysztof Lewandowski; Mieczysław Komarnick 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 84 KB

A staged approach with vincristine, adri

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

✍ C. S. Chim; A. K. W. Lie; E. Y. T. Chan; Y. Y. Leung; S. C. W. Cheung; S. Y. T. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 319 KB

Intermediate doses of melphalan and dexa

Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia

✍ J. Vela-Ojeda; M. García-Ruiz Esparza; A. Rosas-Cabral; Y. Padilla-González; J. 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 62 KB

Phase III study of PSC-833 (valspodar) i

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : A trial of the Eastern Cooperative Oncology Group

✍ William R. Friedenberg; Montserrat Rue; Emily A. Blood; William S. Dalton; Chaim 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views